Significant Psychedelic Experiences Evaluated for Mystical Characteristics Associated with Cannabis Use Reduction and Psychological Flexibility Improvement: A Naturalistic Cross-Sectional Retrospective Survey

References

• Adamson, S. J., and J. D. Sellman. 2003. A prototype screening instrument for cannabis use disorder: The cannabis use disorders identification test (CUDIT) in an alcohol-dependent clinical sample. Drug and Alcohol Review 22 (3):309–15. doi:10.1080/0959523031000154454.
   PubMed Web of Science ®Google Scholar
• Agrawal, A., A. J. Budney, and M. T. Lynskey. 2012. The co‐occurring use and misuse of cannabis and tobacco: A review. Addiction 107 (7):1221–33. doi:10.1111/j.1360-0443.2012.03837.x.
   PubMed Web of Science ®Google Scholar
• Aleksandrova, L. R., and A. G. Phillips. 2021. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends in Pharmacological Sciences 42 (11):929–42. doi:10.1016/j.tips.2021.08.003.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2013 Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Association. doi:10.1176/appi.books.9780890425596.
   Google Scholar
• Barrett, F. S., M. W. Johnson, and R. R. Griffiths. 2015. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology 29 (11):1182–90. doi:10.1177/0269881115609019.
   PubMed Web of Science ®Google Scholar
• Boehnke, K. F., D. J. Kruger, and P. Lucas. 2023. Changed substance use after psychedelic experiences among individuals in Canada. International Journal of Mental Health and Addiction 22 (2):842–53. doi:10.1007/s11469-023-01085-z.
   Web of Science ®Google Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., S. Ross, S. Bhatt, T. Baron, A. A. Forcehimes, E. Laska, S. E. Mennenga, K. O’Donnell, L. T. Owens, S. Podrebarac, et al. 2022. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry 79 (10):953. doi:10.1001/jamapsychiatry.2022.2096.
   PubMed Web of Science ®Google Scholar
• Bond, F. W., S. C. Hayes, R. A. Baer, K. M. Carpenter, N. Guenole, H. K. Orcutt, T. Waltz, and R. D. Zettle. 2011. Preliminary psychometric properties of the acceptance and action questionnaire–II: A revised measure of psychological inflexibility and experiential avoidance. Behavior Therapy 42 (4):676–88. doi:10.1016/j.beth.2011.03.007.
   PubMed Web of Science ®Google Scholar
• Brezing, C. A., and F. R. Levin. 2018. The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology Reviews 43 (1):173–94. doi:10.1038/npp.2017.212.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., S. Chandaria, D. E. Erritzoe, A. Gazzaley, M. Girn, H. Kettner, P. A. M. Mediano, D. J. Nutt, F. E. Rosas, L. Roseman, et al. 2023. Canalization and plasticity in psychopathology. Neuropharmacology, the Neuropharmacology of Social Behavior: From Bench to Bedside 226:109398. doi:10.1016/j.neuropharm.2022.109398.
   Google Scholar
• Carhart-Harris, R. L., K. J. Friston, and E. L. Barker. 2019. REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews 71 (3):316–44. doi:10.1124/pr.118.017160.
   PubMed Web of Science ®Google Scholar
• Close, J. B., E. C. Hajien, R. Watts, L. Roseman, and R. L. Carhart-Harris. 2020. Psychedelics and psychological flexibility – Results of a prospective web-survey using the acceptance and action questionnaire II. Journal of Contextual Behavioral Science 16:37–44. doi:10.1016/j.jcbs.2020.01.005.
   Web of Science ®Google Scholar
• Connor, J. P., D. Stjepanović, B. Le Foll, E. Hoch, A. J. Budney, and W. D. Hall. 2021. Cannabis use and cannabis use disorder. Nature Reviews Disease Primers 7 (1):16. doi:10.1038/s41572-021-00247-4.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., F. S. Barrett, and R. R. Griffiths. 2020. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science 15:39–45. doi:10.1016/j.jcbs.2019.11.004.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, P. H. Finan, and R. R. Griffiths. 2021. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78 (5):481–89. doi:10.1001/jamapsychiatry.2020.3285.
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., F. Charlson, A. Ferrari, D. Santomauro, H. Erskine, A. Mantilla-Herrara, H. Whiteford, J. Leung, M. Naghavi, M. Griswold, et al. 2018. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the global burden of disease study 2016. The Lancet Psychiatry 5 (12):987–1012. doi:10.1016/S2215-0366(18)30337-7.
   PubMed Web of Science ®Google Scholar
• Fauvel, B., S. Kangaslampi, L. Strika-Bruneau, B. Roméo, and P. Piolino. 2022. Validation of a French version of the mystical experience questionnaire with retrospective reports of the most significant psychedelic experience among French users. Journal of Psychoactive Drugs 55 (2):170–79. doi:10.1080/02791072.2022.2059796.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., A. K. Davis, E. Erowid, F. Erowid, R. R. Griffiths, and M. W. Johnson. 2020. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiers in Psychiatry 10:955. doi:10.3389/fpsyt.2019.00955.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., A. K. Davis, F. Erowid, E. Erowid, R. R. Griffiths, and M. W. Johnson. 2019. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology 33 (9):1088–101. doi:10.1177/0269881119845793.
   PubMed Web of Science ®Google Scholar
• Gates, P. J., P. Sabioni, J. Copeland, B. Le Foll, and L. Gowing. 2016. Psychosocial interventions for cannabis use disorder. The Cochrane Database of Systematic Reviews 2016 (5):CD005336. doi:10.1002/14651858.CD005336.pub4.
   PubMedGoogle Scholar
• Glazer, J., C. H. Murray, R. Nusslock, R. Lee, and H. de Wit. 2023. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Neuropsychopharmacology Reviews 48 (2):418–26. doi:10.1038/s41386-022-01479-y.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187 (3):268–83. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Guillem, E., C. Notides, M. Debray, F. Vorspan, C. Musa, M. Leroux, I. Nieto, and J.-P. Lépine. 2011. Psychometric properties of the cannabis use disorders identification test in French cannabis misusers. Journal of Addictions Nursing 22 (4):214–23. doi:10.3109/10884602.2011.616604.
   Web of Science ®Google Scholar
• Gukasyan, N., A. K. Davis, F. S. Barrett, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, and R. R. Griffiths. 2022. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology 36 (2):151–58. doi:10.1177/02698811211073759.
   PubMed Web of Science ®Google Scholar
• Halberstadt, A. L. 2015. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research 277:99–120. doi:10.1016/j.bbr.2014.07.016.
   PubMed Web of Science ®Google Scholar
• Hall, W., and L. Degenhardt. 2009. Adverse health effects of non-medical cannabis use. The Lancet 374 (9698):1383–91. doi:10.1016/S0140-6736(09)61037-0.
   PubMed Web of Science ®Google Scholar
• Hartogsohn, I. 2016. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology 30 (12):1259–67. doi:10.1177/0269881116677852.
   PubMed Web of Science ®Google Scholar
• Heinzerling, K. G., K. Sergi, M. Linton, R. Rich, B. Youssef, I. Bentancourt, J. Bramen, P. Siddarth, L. Schwartzberg, and D. F. Kelly. 2023. Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder. Frontiers in Psychiatry 14:1215972. doi:10.3389/fpsyt.2023.1215972.
   PubMed Web of Science ®Google Scholar
• Hipólito, I., J. Mago, F. Rosas, and R. Carhart-Harris. 2022. Pattern breaking: A complex systems approach to psychedelic medicine [Preprint]. PsyArXiv. doi:10.31234/osf.io/ydu3h.
   Google Scholar
• Ibarra-Lecue, I., I. Mollinedo-Gajate, J. J. Meana, L. F. Callado, R. Diez-Alarcia, and L. Urigüen. 2018. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through akt/mTOR pathway. Neuropsychopharmacology Reviews 43 (10):2028–35. doi:10.1038/s41386-018-0076-y.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W. 2022. Classic psychedelics in addiction treatment: The case for psilocybin in tobacco smoking cessation. Berlin Heidelberg: Springer. doi:10.1007/7854_2022_327.
   Google Scholar
• Johnson, M. W., A. Garcia-Romeu, M. P. Cosimano, and R. R. Griffiths. 2014. Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology 28 (11):983–92. doi:10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, and R. R. Griffiths. 2017. Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43 (1):55–60. doi:10.3109/00952990.2016.1170135.
   PubMed Web of Science ®Google Scholar
• Kangaslampi, S. 2020. Uncovering psychological mechanisms mediating the effects of drugs: Some issues and comments using the example of psychedelic drugs. Psychopharmacology 237 (12):3799–802. doi:10.1007/s00213-020-05703-9.
   PubMedGoogle Scholar
• Kashdan, T. B., and J. Rottenberg. 2010. Psychological flexibility as a fundamental aspect of health. Clinical Psychology Review 30 (7):865–78. doi:10.1016/j.cpr.2010.03.001.
   PubMed Web of Science ®Google Scholar
• Kelmendi, B., S. A. Kichuk, G. DePalmer, G. Maloney, T. H. W. Ching, A. Belser, and C. Pittenger. 2022. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 8 (12):e12135. doi:10.1016/j.heliyon.2022.e12135.
   PubMed Web of Science ®Google Scholar
• Kervadec, E., B. Fauvel, L. Strika-Bruneau, A. Amirouche, V. Verroust, P. Piolino, B. Romeo, and A. Benyamina. 2023. Reduction of alcohol use and increase in psychological flexibility after a naturalistic psychedelic experience: A retrospective survey. Alcohol & Alcoholism 59 (2). doi:10.1093/alcalc/agad078.
   Web of Science ®Google Scholar
• Krebs, T. S., and P.-Ø. Johansen. 2012. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology 26 (7):994–1002. doi:10.1177/0269881112439253.
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., K. H. Preller, P. R. Corlett, A. Anticevic, and A. P. Kaye. 2023. Psychedelics and the neurobiology of meaningfulness. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 9 (5):S462–463. doi:10.1016/j.bpsc.2023.09.003.
   PubMedGoogle Scholar
• Kuypers, K. P. C., J. Riba, M. de la Fuente Revenga, S. Barker, E. L. Theunissen, and J. G. Ramaekers. 2016. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology 233 (18):3395–403. doi:10.1007/s00213-016-4377-8.
   PubMed Web of Science ®Google Scholar
• Lebedev, A. V., M. Kaelen, M. Lövdén, J. Nilsson, A. Feilding, D. J. Nutt, and R. L. Carhart-Harris. 2016. LSD-induced entropic brain activity predicts subsequent personality change: LSD-Induced entropic brain activity. Human Brain Mapping 37 (9):3203–13. doi:10.1002/hbm.23234.
   PubMed Web of Science ®Google Scholar
• Ly, C., A. C. Greb, L. P. Cameron, J. M. Wong, E. V. Barragan, P. C. Wilson, K. F. Burbach, S. Soltanzadeh Zarandi, A. Sood, M. R. Paddy, et al. 2018. Psychedelics promote structural and functional neural plasticity. Cell Reports 23 (11):3170–82. doi:10.1016/j.celrep.2018.05.022.
   PubMed Web of Science ®Google Scholar
• Maclean, K. A., J.-M. S. Leoutsakos, M. W. Johnson, and R. R. Griffiths. 2012. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion 51 (4):721–37. doi:10.1111/j.1468-5906.2012.01685.x.
   PubMed Web of Science ®Google Scholar
• Madsen, M. K., P. M. Fisher, D. Burmester, A. Dyssegaard, D. S. Stenbæk, S. Kristiansen, S. S. Johansen, S. Lehel, K. Linnet, C. Svarer, et al. 2019. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology Reviews 44 (7):1328–34. doi:10.1038/s41386-019-0324-9.
   PubMed Web of Science ®Google Scholar
• Moliner, R., M. Girych, C. A. Brunello, V. Kovaleva, C. Biojone, G. Enkavi, L. Antenucci, E. F. Kot, S. A. Goncharuk, K. Kaurinkoski, et al. 2023. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nature Neuroscience 26 (6):1032–41. doi:10.1038/s41593-023-01316-5.
   PubMed Web of Science ®Google Scholar
• Monestès, J.-L., M. Villatte, H. Mouras, G. Loas, and F. W. Bond. 2009. Traduction et validation française du questionnaire d’acceptation et d’action (AAQ-II). European Review of Applied Psychology 59 (4):301–08. doi:10.1016/j.erap.2009.09.001.
   Web of Science ®Google Scholar
• Moore, T. H., S. Zammit, A. Lingford-Hughes, T. R. Barnes, P. B. Jones, M. Burke, and G. Lewis. 2007. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. The Lancet 370 (9584):319–28. doi:10.1016/S0140-6736(07)61162-3.
   PubMed Web of Science ®Google Scholar
• Murtha, L., P. Sathiadoss, J.-P. Salameh, M. D. F. Mcinnes, and G. Revah. 2023. Chest CT findings in marijuana smokers. Radiology 307 (1):e212611. doi:10.1148/radiol.212611.
   PubMed Web of Science ®Google Scholar
• Olson, D. E. 2022. Biochemical mechanisms underlying psychedelic-induced neuroplasticity. Biochemistry 61 (3):127–36. doi:10.1021/acs.biochem.1c00812.
   PubMed Web of Science ®Google Scholar
• Phan, A. N., and G. E. Terry. 2023. Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder. Frontiers in Psychiatry 14:1144276. doi:10.3389/fpsyt.2023.1144276.
   PubMed Web of Science ®Google Scholar
• Raison, C. L., R. Jain, A. D. Penn, S. P. Cole, and S. Jain. 2022. Effects of naturalistic psychedelic use on depression, anxiety, and well-being: Associations with patterns of use, reported harms, and transformative mental states. Frontiers in Psychiatry 13:831092. doi:10.3389/fpsyt.2022.831092.
   PubMed Web of Science ®Google Scholar
• Romeo, B., B. Fauvel, S. Dejean, L. Strika, A. Amirouche, V. Verroust, P. Piolino, and A. Benyamina. 2023. Impact of a naturalistic psychedelic experience on smoking: A retrospective survey. Journal of Psychoactive Drugs 55 (5):640–49. doi:10.1080/02791072.2023.2227171.
   PubMed Web of Science ®Google Scholar
• Romeo, B., M. Hermand, A. Pétillion, L. Karila, and A. Benyamina. 2021. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. Journal of Psychiatric Research 137:273–82. doi:10.1016/j.jpsychires.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Roseman, L., D. J. Nutt, and R. L. Carhart-Harris. 2018. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology 8:974. doi:10.3389/fphar.2017.00974.
   PubMed Web of Science ®Google Scholar
• Rosenblat, J. D., M. Leon-Carlyle, S. Ali, M. I. Husain, and R. S. McIntyre. 2023. Antidepressant effects of psilocybin in the absence of psychedelic effects. American Journal of Psychiatry 180 (5):395–96. doi:10.1176/appi.ajp.20220835.
   PubMed Web of Science ®Google Scholar
• Ross, S. 2012. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatric Clinics of North America 35 (2):357–74. doi:10.1016/j.psc.2012.04.002.
   PubMed Web of Science ®Google Scholar
• Sharma, R., R. Batchelor, and J. Sin. 2023. Psychedelic treatments for substance use disorder and substance misuse: A mixed methods systematic review. Journal of Psychoactive Drugs 55 (5):612–30. doi:10.1080/02791072.2023.2190319.
   PubMed Web of Science ®Google Scholar
• Singh, A., S. Saluja, A. Kumar, S. Agrawal, M. Thind, S. Nanda, and J. Shirani. 2018. Cardiovascular complications of Marijuana and related substances: A review. Cardiology and Therapy 7 (1):45–59. doi:10.1007/s40119-017-0102-x.
   PubMed Web of Science ®Google Scholar
• Thomas, G., P. Lucas, N. Capler, K. Tupper, and G. Martin. 2013. Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Current Drug Abuse Reviews 6 (1):30–42. doi:10.2174/15733998113099990003.
   PubMedGoogle Scholar
• Ubhayarathna, M., C. J. Langmead, N. A. Diepenhorst, and G. D. Stewart. 2023. Molecular and structural insights into the 5-HT2C receptor as a therapeutic target for substance use disorders. British Journal of Pharmacology. doi:10.1111/bph.16233.
   PubMed Web of Science ®Google Scholar
• UNODC. 2020. United Nations Office on Drugs and Crime (UNODC) (2020). World Drug Report 2020. https://wdr.unodc.org/wdr2020/index2020.html.
   Google Scholar
• Vollenweider, F. X., M. F. I. Vollenweider-Scherpenhuyzen, A. Bäbler, H. Vogel, and D. Hell. 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9 (17):3897–902. doi:10.1097/00001756-199812010-00024.
   PubMed Web of Science ®Google Scholar
• Walsh, Z., and M. S. Thiessen. 2018. Psychedelics and the new behaviourism: Considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. International Review of Psychiatry (Abingdon, England) 30 (4):343–49. doi:10.1080/09540261.2018.1474088.
   PubMed Web of Science ®Google Scholar
• Wirsching, A., T. Bostoen, and A. C. Huizink. 2023. A psychometric evaluation of the Dutch revised mystical experience questionnaire. Journal of Psychoactive Drugs 1–11. doi:10.1080/02791072.2023.2272832.
   PubMed Web of Science ®Google Scholar